Want to see HK:9887 full AI Analyst Report?
Top Page
Nanjing Leads Biolabs Co., Ltd. Class H
(9887)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$55.00
▼(-40.22% Downside)
Action:Reiterated
Date:09/16/26
The score is primarily constrained by weak financial performance—large ongoing losses and persistent negative operating/free cash flow—despite an improved equity position and more moderate leverage. Technicals further weigh on the score, with the stock trading below key moving averages and negative MACD momentum. Valuation contributes modestly negatively due to a loss-driven negative P/E and no dividend yield data.
Positive Factors
Balance-sheet improvement
The return to strongly positive equity materially improves the company’s capital structure compared with its earlier stressed position. Moderate leverage in 2025 provides greater financial flexibility and a more stable base for continuing development, even though debt remains meaningful.
Negative Factors
Persistent cash burn
Repeatedly negative operating and free cash flow show that the business is not yet self-funding its operations. Continued cash consumption can increase reliance on external funding, reduce strategic flexibility, and make progress toward sustainable growth dependent on improving operating economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet improvement
The return to strongly positive equity materially improves the company’s capital structure compared with its earlier stressed position. Moderate leverage in 2025 provides greater financial flexibility and a more stable base for continuing development, even though debt remains meaningful.
Read all positive factors
Nanjing Leads Biolabs Co., Ltd. Class H (9887) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$12.23B
Dividend YieldN/A
Average Volume (3M)1.92M
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth6.66%
CountryHK
Employees244
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding197,670,290
10 Day Avg. Volume2,003,805
30 Day Avg. Volume1,921,923
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)6.30
Price to Sales (P/S)40.45
P/FCF Ratio-48.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$95.95Price Target Upside4.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nanjing Leads Biolabs Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic end...
Nanjing Leads Biolabs Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 231.45M | 197.20M | 0.00 | 9.75M | 0.00 |
| Gross Profit | 231.45M | 197.20M | 0.00 | 6.25M | -17.78M |
| EBITDA | -208.38M | -199.03M | -36.89M | -267.93M | -195.76M |
| Net Income | -271.59M | -235.21M | -43.90M | -398.61M | -286.77M |
Balance Sheet | |||||
| Total Assets | 1.54B | 1.78B | 669.44M | 447.48M | 615.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24B | 1.55B | 538.72M | 347.65M | 486.56M |
| Total Debt | 373.39M | 280.56M | 266.48M | 67.09M | 1.19B |
| Total Liabilities | 608.15M | 515.61M | 403.88M | 1.40B | 1.21B |
| Stockholders Equity | 930.83M | 1.27B | 265.56M | -948.80M | -597.95M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -164.84M | -121.79M | -204.41M | -74.37M |
| Operating Cash Flow | 0.00 | -154.43M | -118.82M | -192.69M | -44.62M |
| Investing Cash Flow | 0.00 | -165.13M | -67.30M | 135.49M | 55.24M |
| Financing Cash Flow | 0.00 | 1.19B | 309.02M | 49.49M | -3.18M |
Nanjing Leads Biolabs Co., Ltd. Class H Technical Analysis
Negative
92.00
Price Trends
63.83
Negative
63.35
Negative
62.73
Negative
Market Momentum
-1.50
Positive
36.16
Neutral
15.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9887, the sentiment is Negative. The current price of 92 is above the 20-day moving average (MA) of 67.24, above the 50-day MA of 63.83, and above the 200-day MA of 62.73, indicating a bearish trend. The MACD of -1.50 indicates Positive momentum. The RSI at 36.16 is Neutral, neither overbought nor oversold. The STOCH value of 15.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9887.
Nanjing Leads Biolabs Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$204.22B | 34.80 | 10.51% | ― | 21.93% | 21.94% | |
66 Neutral | HK$26.42B | 57.37 | 15.94% | ― | 48.04% | 166.72% | |
62 Neutral | HK$74.44B | -13.82 | -16.23% | 0.35% | 53.48% | -120.02% | |
60 Neutral | HK$2.72B | 13.39 | 4.45% | 0.27% | 7.38% | 7.90% | |
59 Neutral | HK$82.83B | 43.67 | 10.96% | 0.80% | 20.39% | 26.48% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | HK$12.23B | -35.40 | -23.34% | ― | ― | 6.66% |
* General Sector Average
HK:9887
Nanjing Leads Biolabs Co., Ltd. Class H
57.10
-12.65
-18.14%
HK:1548
Genscript Biotech
32.38
15.35
90.14%
HK:2269
Wuxi Biologics (Cayman)
49.22
10.46
26.99%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
28.84
0.88
3.13%
HK:1873
Viva Biotech Holdings
1.29
-1.42
-52.41%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
57.00
30.50
115.09%
Nanjing Leads Biolabs Co., Ltd. Class H Corporate Events
Nanjing Leads Biolabs’ Bispecific Antibody LBL-024 Shows Strong First-Line NSCLC Data
Sep 14, 2026
Nanjing Leads Biolabs reported updated Phase II data for its self-developed PD-L1/4–1BB bispecific antibody LBL-024 combined with chemotherapy as a first-line therapy for non-small cell lung cancer, presented at the 2026 World Conference on ...
Nanjing Leads Biolabs Advances Next-Generation Immuno-Oncology Pipeline Toward First-in-Class Approval
Aug 31, 2026
Nanjing Leads Biolabs reported substantial progress across registration, clinical development, platform advancement and commercialization preparations in the first half of 2026, underscoring its ambition to become a global frontrunner in next-gene...
Nanjing Leads Biolabs Advances Key Immunotherapy LBL-024 in Esophageal Cancer Trial
Aug 24, 2026
Nanjing Leads Biolabs said its self-developed bispecific antibody LBL-024, branded as Opamtistomig, has moved into the expansion stage of a Phase II trial as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcin...
Nanjing Leads Biolabs’ PD-L1/4-1BB Cancer Drug Wins Priority Review in China
Aug 21, 2026
Nanjing Leads Biolabs said China’s National Medical Products Administration has accepted the new drug application for LBL-024, a self-developed PD-L1/4-1BB bispecific antibody, as monotherapy for previously treated advanced extrapulmonary ne...
Leads Biolabs touts promising Phase II data for NSCLC bispecific antibody LBL-024
Aug 20, 2026
Nanjing Leads Biolabs announced that the full abstract of its Phase II clinical study of LBL-024, a PD-L1/4-1BB bispecific antibody, combined with chemotherapy as first-line treatment for non-small cell lung cancer has been published on the World ...
Oblenio Exercises License Option for Nanjing Leads Biolabs’ Autoimmune Drug LBL-051
Aug 19, 2026
Nanjing Leads Biolabs has reported that Oblenio Bio, Inc., a U.S. company formed by Aditum Bio, has exercised its option to retain an exclusive worldwide license to develop, manufacture and commercialize LBL-051, a trispecific T-cell engager disco...
Nanjing Leads Biolabs Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 19, 2026
Nanjing Leads Biolabs Co., Ltd. has scheduled a board meeting for August 31, 2026 to review and approve the interim results for the six months ended June 30, 2026. The board will also consider whether to recommend the payment of a dividend, a deci...
Nanjing Leads Biolabs Advances Key Liver Cancer Trial for Opamtistomig
Aug 5, 2026
Nanjing Leads Biolabs has reported that its Phase II clinical study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for first-line treatment of hepatocellular carcinoma has successfully completed the safety run-in assessment and ente...
Nanjing Leads Biolabs Advances Autoimmune Drug LBL-051 Into First-in-Human Trial
Aug 4, 2026
Nanjing Leads Biolabs announced that its partner Oblenio Bio has dosed the first patients in a Phase Ia, first-in-human clinical trial in Europe of LBL-051, a trispecific T-cell engager targeting BCMA, CD19 and CD3 for refractory autoimmune diseas...
Nanjing Leads Biolabs Wins IND Nod for Bispecific Antibody in Metastatic Colorectal Cancer
Aug 2, 2026
Nanjing Leads Biolabs has received approval from China’s National Medical Products Administration for an Investigational New Drug application for LBL-024, a PD-L1/4-1BB bispecific antibody, in metastatic colorectal cancer. The open-label, mu...
Nanjing Leads Biolabs Completes Phase II Enrollment for Opamtistomig in Biliary Tract Cancer
Jul 30, 2026
Nanjing Leads Biolabs has completed full patient enrollment in a Phase II clinical study of its PD-L1/4-1BB bispecific antibody LBL-024 (Opamtistomig) as first-line therapy for advanced biliary tract cancer. All 70 patients were enrolled rapidly a...
Nanjing Leads Biolabs CEO Extends Lock-Up, Signaling Confidence in Long-Term Prospects
Jul 24, 2026
Nanjing Leads Biolabs Co., Ltd. announced that its co-founder, chairman and chief executive officer, Dr. Kang Xiaoqiang, has voluntarily extended the lock-up period on all 7,874,617 H shares he directly holds. The original 12-month lock-up from th...
Nanjing Leads Biolabs Wins Key ESMO Slots as Flagship Immunotherapy Assets Gain Momentum
Jul 13, 2026
Nanjing Leads Biolabs announced that six of its latest oncology studies have been selected for presentation at the 2026 ESMO annual meeting, including two top-tier Proffered Papers and four posters across extrapulmonary neuroendocrine carcinoma, b...
Nanjing Leads Biolabs’ LBL-024 for EP-NEC Enters China Priority Review
Jul 10, 2026
Nanjing Leads Biolabs has announced that its biologics license application for LBL-024, a PD-L1/4-1BB bispecific antibody branded as Opamtistomig, for monotherapy in advanced extrapulmonary neuroendocrine carcinoma has been accepted into ChinaR...
Nanjing Leads Biolabs Grants Over 2.25 Million H Share Awards to Staff Under Incentive Scheme
Jul 1, 2026
Nanjing Leads Biolabs has granted a total of 2,254,691 H share awards to 149 employees under its H Share Award Scheme, including executive director and CFO Mr. Zuo, with all awards satisfied by existing shares acquired on the market to avoid dilut...
Nanjing Leads Biolabs’ JV Secures US$62 Million to Advance Trispecific Autoimmune Therapy
Jun 25, 2026
Nanjing Leads Biolabs announced that its joint venture with Aditum Bio, Oblenio Bio, has closed an oversubscribed US$62 million Series B round led by Pfizer Ventures, joined by Deep Track Capital, GV and Aditum Bio, to advance clinical development...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.